Document:

Exhibit 10.16

 

	

 

May 19, 2014

 

PRIVATE AND CONFIDENTIAL

 

Michael “Mike” Lehmann 

2401 Victoria Park Lane 

Raleigh,
NC 27614

 

		RE:	Amendment to Employment Contract

 

Dear Mike:

 

Further to our discussions, this letter (the “Letter”),
effective as of June 9, 2014 (the “Amendment Effective Date”), confirms that Patheon Pharmaceutical Services Inc. (the
“Company”), has agreed to increase your base salary in your current role of President, Global PDS, and has further
agreed to provide you with the equity grant described below. Once signed, this Letter will serve as the first amendment to the
Employment Agreement between you and the Company dated November 1, 2012 (collectively, the “Employment Agreement”).
Any terms used in this Letter that are not defined herein have the definition ascribed to them in the Employment Agreement.

 

For purposes of clarity, please be advised that the Company
is a subsidiary of DPx Holdings B.V. (“DPx”). DPx the corporate parent of a group of businesses engaged in the provision
of commercial manufacturing and development services (pharmaceuticals and fine chemicals), related services, and the development,
manufacture, distribution and marketing of proprietary products. The Company serves as the corporate shared services entity for
DPx and other members of the DPx Group.

 

		1.	General Provisions

 

This Letter, when fully executed, together with the
Employment Agreement, reflects the entire agreement regarding the terms and conditions of your employment and promotion. Unless
expressly modified by this Letter, the terms and conditions of the Employment Agreement, including without limitation your confidentiality,
assignment of inventions, non-solicitation and non-competition undertakings, will remain the same.

 

		2.	Compensation & Benefits

 

		a.	Base Salary: In recognition of your performance, your annual base salary will be increased to $415,000 subject to standard
withholdings and deductions and payable in regular installments in accordance with the Company’s normal payroll practices.

 

	 	 	 	 	 

 

    	 

    	 

    

 

		b.	Equity Incentive Plan:

 

(i)          You
shall be eligible to participate in the JLL/DELTA PATHEON HOLDINGS, L.P. 2014 Equity Incentive Plan (the “MEIP”) and
shall be eligible to be awarded Membership Units from time to time in accordance with the terms of such MEIP, the Membership Unit
award agreement, and all related documents (collectively, the MEIP Related Documents”).

 

(ii)          Subject
to approval of the Board of Directors at a meeting following the Effective Date, you will be awarded four thousand (4,000) of the
Membership Units, which shall be granted subject to the MEIP Related Documents. You will be required to comply with the MEIP Related
Documents, as amended from time to time.

 

3. Other Benefits: All other compensation and
benefits terms (including without limitation, severance terms and post-employment restrictions) shall be as provided in your Employment
Agreement. For purposes of clarity, any changes, modifications, or additions to your compensation and benefits terms require the
review and approval of Patheon’s Compensation and Human Resources Committee (i.e., cannot be approved at the Company level).

 

[SIGNATURE PAGE FOLLOWS]

 

	 	 	 	 	Page | 2

 

    	 

    	 

    

 

By executing this Letter, you confirm your decision to accept
the amendment to the terms of your Employment Agreement and you agree that your employment will be governed by the Employment
Agreement, as amended by this Letter. 

	 	 
	 	Very truly yours,
	 	 
	 	Patheon Pharmaceutical Services Inc.
	 	 
	 	James C. Mullen 

Chief Executive Officer

 

Read, understood, consented, and agreed as of this 17 day of
June, 2014: 

	 	 	 	 
	SIGNED, SEALED AND DELIVERED

    in the presence of

     

	 	)

                                    )

				    )

                                    )

                                    )

                                    )
	
	Name of Witness:	 	 	Michael Lehmann

 

	 	 	 	 	Page | 3Exhibit 10.17

 

	

 

	 	James C. Mullen 
	 	Chief Executive Officer 

Patheon 
	 	U.S. Headquarters 
	 	4721 Emperor Blvd., Suite 200 
	 	Durham, North Carolina 27703 

 

25 January 2011

 

PRIVATE AND CONFIDENTIAL 

 

		RE:	Terms of Employment 

 

Stuart Grant 

15604 Frohock Place 

Charlotte, NC 28277

 

Dear Stuart:

 

Further to our discussions, I am pleased to present these terms
of employment to you with Patheon Pharmaceutical Services Inc. (the “Company”) to serve as Chief Financial Officer.
Attached hereto, as Exhibit A, is a summary of the key terms of your employment arrangement. Your employment will be governed by
the terms set forth on Exhibit A, subject to the execution of an employment agreement between you and the Company on substantially
the terms set forth on Exhibit A (the “Employment Agreement”).

 

By executing this letter, you agree that your employment will
be governed by the terms set forth on Exhibit A, subject to the final execution of the Employment Agreement.

 

Stuart, I am looking forward to working with you.

 

Very truly yours,

 

Patheon Pharmaceuticals Services Inc.

 

	 
	James C. Mullen 
	Chief Executive Officer 

 

Accepted as of this 27th day of January, 2012: 

 

	 	 
	Stuart Grant	 

 

		  Performance the World Over

 

    	 

    	 

    

 

	

 

EXHIBIT A 

 

Summary of Key Terms

For Proposed Employment between Patheon Pharmaceutical Services Inc. 

(the “Company”)

and

Stuart Grant (“Executive”)

 

		1.	Title: Chief Financial Officer. Position reports to the Chief Executive Officer (“CEO”).

 

The Company is a subsidiary of Patheon Inc. (“Patheon”).
Patheon is in the business of providing its customers with pharmaceutical development services, clinical trial manufacturing and
packaging and commercial manufacturing and packaging. The Company serves as the corporate shared services entity for Patheon and
other members of the Patheon Group. As used herein, “Patheon Group” means Patheon and any entity controlled by Patheon.

 

		2.	Term and Effective Date 

 

Indefinite term with an expected start date of February
13, 2012 (“Effective Date”).

 

		3.	Location of Duties 

 

The Executive’s principal office will be at
the US Headquarters location in Durham, North Carolina. The Executive will be required to relocate to Raleigh/Durham area as a
condition employment. The Executive will be eligible for relocation assistance in accordance with the North American Tier 1 program.
The move must be completed within 12 months of the Effective Date.

 

		4.	Direct Reports and Functional Responsibility 

 

The Executive will serve as the Chief Financial Officer,
with such authority, duties and responsibilities as are commensurate with such position, reporting to the CEO. In addition, the
Executive will be a member of the Patheon Group’s Executive Committee and will become an officer of Patheon and of any members
of the Patheon Group as may be requested.

 

The Executive will have responsibility for leading
Patheon’s Finance function.

 

		5.	Base Salary

 

$430,000 annually (“Base Salary”),
payable in regular installments in accordance with the Company’s normal payroll practices. Executive’s base
salary will be reviewed during the normal Performance cycle following close of the 2012 fiscal year. Any increase to base
salary will be awarded in the same time frame as other similarly situated executives receiving Performance
based merit awards.

 

		  Performance the World Over

 

    	 

    	 

    

 

	

 

		6.	Performance Bonus

 

Executive will be eligible to receive a target performance
bonus of forty-five percent (45%) of Executive’s Base Salary, based on achieving predetermined financial and other targets
recommended by the Chief Executive Officer. For fiscal 2012, any Performance bonus will be prorated from the Effective Date.

 

		7.	Equity Compensation - Stock Options 

 

Executive will be eligible to participate in Patheon’s
2011 Amended and Restated Incentive Stock Option Plan (the “Stock Option Plan”) and to be awarded stock options from
time to time in accordance with the terms of such Plan and related stock option award agreement (together, with the Stock Option
Plan, the “Stock Option Related Documents”).

 

Subject to approval of the Board of Directors of Patheon
(the “Board”) at a meeting following the Effective Date, the Executive will be granted options to acquire 425,000 of
Patheon’s restricted voting shares, subject to the Stock Option Related Documents. Except as otherwise provided in the Stock
Option Related Documents, the options will vest in five (5) equal installments on each of the first five (5) anniversaries of the
Effective Date, subject to the Executive’s continued employment with the Patheon Group until the relevant vesting dates.
The subscription price for the shares under option will be the market price (as defined in the Stock Option Plan) on the date of
grant. All options granted to the Executive will expire ten (10) years from the date of grant.

 

During the Executive’s employment, at the discretion
of the Board or its delegate, the Executive also will be eligible to receive additional stock options and other long-term incentives
under the Stock Option Plan or any similar plan adopted by Patheon from time to time in the course of its periodic review of executive
compensation arrangements.

 

Executive will be expected to comply with the terms
of any share ownership guidelines implemented by Patheon, as amended from time to time.

 

		8.	Employee Benefits 

 

Executive will be entitled to participate in all employee
healthcare and welfare benefits programs of the Company, in accordance with the then applicable terms, conditions and eligibility
requirements of such programs that are offered from time to time to U.S. resident-based employees at the Executive’s level,
including medical, dental, life insurance, 401k retirement plans and other health benefit programs. The Company will pay the Executives
ArmadaCare premiums during 2012.

 

In addition, the Executive will be entitled to four
(4) weeks of vacation time, subject to the Company’s vacation policy, as may be in effect from time to time, which will be
pro-rated based on the Effective Date. Further, the Executive will be entitled to four (4) floating holidays annually (one of which
is designated to be December 31, 2012) and
twenty-four (24) hours for emergency time off annually, each in accordance with the Company’s policies, as may be in effect
from time to time, and pro-rated based on the Effective Date.

 

		  Performance the World Over

 

    	 

    	 

    

 

	

 

		9.	Severance

 

In the event the Executive’s employment is terminated
by the Company without Cause (as defined below) or if the Executive terminates employment with the Company for Good Reason (as
defined below), the Executive will be entitled to receive an amount equal to (i) twelve (12) months Base Salary and (ii) an additional
amount, determined by the Company in its sole discretion, equal to the bonus he would reasonably be expected to have earned during
the fiscal year in which his employment is terminated. The Executive will be entitled to this severance benefit only if he executes
and does not revoke a Company-drafted waiver and release within a prescribed time period following termination of employment.

 

The severance benefit described above will generally
be paid in equal installments over twelve (12) months, beginning after the date the waiver and release becomes irrevocable. However,
to the extent that the Executive’s severance payment exceeds two times the lesser of (i) the Executive’s annual compensation
or (ii) the compensation limit in effect under Section 401(a)(17) of the Internal Revenue Code of 1986, as amended, for the calendar
year including the date of termination, any amounts not yet paid as of the “short-term deferral date” will be paid
in a lump sum on the “short-term deferral date.” The “short-term deferral date” is the date that is two
and one-half months after the end of the later of (i) the calendar year in which the Executive’s employment is terminated
or (ii) the Company’s fiscal year in which the Executive’s employment is terminated.

 

“Good Reason” means the occurrence
of any of the following events without the consent of the Executive: (i) a material reduction of the Executive’s duties or
responsibilities or the assignment to the Executive of duties or responsibilities or the assignment to the Executive of duties
materially inconsistent with such position or (ii) a material breach by the Company of the Employment Agreement. A termination
of the Executive’s employment by Executive will not be deemed to be for Good Reason unless (i) the Executive gives notice
to the Company of the existence of the event or condition constituting Good Reason within thirty (30) days after such event or
condition initially occurs or exists, (ii) the Company fails to cure such event or condition within thirty (30) days after receiving
such notice, and (iii) the Executive’s “separation from service” within the meaning of Section 409A of the Code
occurs not later than ninety (90) days after such event or condition initially occurs or exists.

 

In the event of termination for Cause, the Executive
will not be entitled to severance.

 

“Cause” means the determination,
in good faith, by the Board, after notice to the Executive, that one or more of the following events has occurred: (i) Executive
has failed to perform his material duties, and such failure has not been cured after a period of thirty (30) days notice from
the Company; (ii) any reckless or grossly negligent act by Executive having the effect of injuring the interest, business, or
reputation of the Company or member of the Patheon Group in any material respect; (iii) Executive’s commission of any felony
(including entry of a nolo contendre plea); (iv) any misappropriation or embezzlement of the property of the Company or
any member of the Patheon Group; or (v) a breach of any material provision of the Employment Agreement by Executive, which breach,
if curable, remains uncured for a period of thirty (30) days after receipt by Executive of notice from the Company of such breach.

  

		  Performance the World Over

 

    	 

    	 

    

 

	

 

		10.	Change in Control 

 

In the event that the Executive’s employment
is terminated by the Company without Cause or terminated by the Executive for Good Reason at any time during the six (6) month
period following a Change in Control, then (i) the Executive will be entitled to receive those amounts set forth in Section 9 (“Severance”)
above, and (ii) the unvested portion of the options granted to the Executive hereunder will become immediately vested and exercisable
and remain in force for the duration of their original term.

 

“Change in Control” means any of
the following events:

 

(i) Any “Person” (within the meaning of
Section 13(d)(3) or 14(d)(2) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), other than JLL
Partners or its affiliates, becomes a Beneficial Owner (within the meaning of Exchange Act Rule 13d-3) of more than fifty percent
(50%) of the voting power of the then outstanding voting securities of Patheon entitled to vote generally in the election of directors;

 

(ii) There is consummated a merger or consolidation
of Patheon or any direct or indirect subsidiary of Patheon with any other company, other than a merger or consolidation that would
result in the voting securities of Patheon outstanding immediately prior to such merger or consolidation continuing to represent
(either by remaining outstanding or by being converted into voting securities of the surviving entity or any parent thereof) at
least fifty percent (50%) of the combined voting power of the securities of Patheon or such surviving entity or any parent thereof
outstanding immediately after such merger or consolidation; or

 

(iii) The stockholders of Patheon approve a plan of
complete liquidation or dissolution of the company or there is consummated an agreement for the sale or disposition by Patheon
of all or substantially all of its assets.

 

However, in no event will a “Change in Control”
be deemed to have occurred solely because Patheon (or any member of the Patheon Group) engages in an internal reorganization, which
may include a transfer of assets to, or a merger or consolidation with, one or more affiliates.

  

		  Performance the World Over

 

    	 

    	 

    

 

	

 

		11.	Other

 

The Executive will execute confidentiality, invention
assignment, one year non-solicit/no-hire, and one year non-competition covenants.

 

The Executive represents that he is under no employment
contract, non- competition or other covenants or restrictions that could limit his ability to commence work on the Effective Date
or otherwise limit his ability to perform all responsibilities of the position.

 

		14.	Governing Law

 

North Carolina

 

		15.	Section 409A Compliance

 

While it is the intent of Patheon that the compensation
and benefits described in this summary will be exempt from, or comply with, Section 409A of the Internal Revenue Code (“Section
409A”) the tax treatment of such compensation and benefits is not warranted or guaranteed. The terms of employment described
in this summary will be reflected in the Employment Agreement, which will also include further provisions addressing exemption
from or compliance with Section 409A. The Executive will have the opportunity to have the Employment Agreement reviewed by counsel
prior to signature. In order to comply with Section 409A, the Employment Agreement must be finalized by the end of the calendar
year that includes the Effective Date.

 

		  Performance the World Over

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00249-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00249-of-00352.parquet"}]]